AEON Biopharma, Inc. (AEON)
About AEON Biopharma, Inc.
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.
This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.
Financial summary
- Net income
- -$39.2M
- Total assets
- $5.6M
- Market cap
- $11.1M
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $11.1M
- Shares outstanding
- 46.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 24, 2023
AEON Biopharma, Inc. (AEON) Stock Price
- Reported a net loss of $39.2M.
- Trading 83% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review AEON Biopharma, Inc..
Write a review
News about AEON Biopharma, Inc.
News & sentiment via Polygon.io
AEON Biopharma, Inc.: frequently asked questions
Is AEON Biopharma, Inc. an American company?
AEON Biopharma, Inc. is a US-based company headquartered in Irvine, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is AEON Biopharma, Inc. headquartered?
AEON Biopharma, Inc. is headquartered in Irvine, California, United States.
Is AEON Biopharma, Inc. publicly traded?
Yes — AEON Biopharma, Inc. is a publicly traded company. Its stock trades under the ticker symbol AEON on the NYSE.
What does AEON Biopharma, Inc. do?
AEON Biopharma, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
